ID   MN-1
AC   CVCL_W126
DR   Wikidata; Q54906255
RX   DOI=10.1063/1.1291135;
RX   DOI=10.5795/jjscc.32.1;
RX   PubMed=8718548;
RX   PubMed=15677628;
RX   PubMed=19154404;
RX   PubMed=22246397;
CC   Population: Japanese.
CC   Doubling time: 29.4 hours (Note=At 47th passage) (DOI=10.5795/jjscc.32.1).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C4026; Ovarian mucinous cystadenocarcinoma
DI   ORDO; Orphanet_398961; Mucinous adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   66Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 29-06-23; Version: 8
//
RX   DOI=10.1063/1.1291135;
RA   Kiyozuka Y., Takemoto K., Yamamoto A., Guttmann P., Tsubura A.,
RA   Kihara H.;
RT   "X-ray microimaging of cisplatin distribution in ovarian cancer
RT   cells.";
RL   AIP Conf. Proc. 507:153-153(2000).
//
RX   DOI=10.5795/jjscc.32.1;
RA   Yoshida M., Kiyozuka Y., Noda T., Imai S., Ichijo M.;
RT   "Establishment and characterization of human cell line derived from
RT   mucinous cystadenocarcinoma of ovary.";
RL   Nihon Rinsho Saibo Gakkai Zasshi 32:1-8(1993).
//
RX   PubMed=8718548;
RA   Murakami F.;
RT   "Cytotoxic action of monoclonal antibodies OC125 and SH-9 on ovarian
RT   cancer cell lines.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 48:125-132(1996).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=19154404; DOI=10.1111/j.1349-7006.2008.01065.x;
RA   Sato S., Itamochi H., Kigawa J., Oishi T., Shimada M., Sato S.,
RA   Naniwa J., Uegaki K., Nonaka M., Terakawa N.;
RT   "Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an
RT   effective regimen for mucinous adenocarcinoma of the ovary: a
RT   potential treatment strategy.";
RL   Cancer Sci. 100:546-551(2009).
//
RX   PubMed=22246397; DOI=10.3892/or.2012.1626;
RA   Sato N., Saga Y., Mizukami H., Wang D., Fujiwara H., Takei Y.,
RA   Machida S., Ozawa K., Suzuki M.;
RT   "Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor
RT   cells lacking KRAS gene mutations.";
RL   Oncol. Rep. 27:1336-1340(2012).
//